Augmentation of the Antidepressant Action of Sertraline With Triiodothyronine (T3)and Reboxetine: Clinical Efficacy, Adverse Effects and Predictors of Response.

• Status: Completed
• Trial end date: 2011-08-01

Summary

In this project we aim to further refine indications for the use of the thyroid hormone - T3 for patients suffering from depression. We aim to identify a sub-group of patients who are more likely to respond to T3 and establish the time in the treatment course when T3 should be added. The results of this project could have significant, direct clinical implications.

• Phase: N/A

Details

• Lead Sponsor: Hadassah Medical Organization
• Treatments: Antidepressive Agents; Reboxetine; Sertraline